Gonadotropin-releasing hormone antagonists

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 6, 2000, Pages 350-356

  Fluker, M R ^a  

^a Genesis Fertility Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZALINE B; BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; ITURELIX; LEUPRORELIN; NAFARELIN; TEVERELIX; TRIPTORELIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIOSIS; HIRSUTISM; HORMONE INHIBITION; HUMAN; INFERTILITY THERAPY; LUTEINIZING HORMONE RELEASE; OVARY HYPERSTIMULATION; PRECOCIOUS PUBERTY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; UTERUS MYOMA;

EID: 0033668136     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200012000-00010     Document Type: Review

References (53)

1. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometry-decapeptide-Edman degradation)
2. Structure of the porcine LH- and FSH- releasing hormone. I. The proposed amino acid sequence
3. Isolation and properties of the FSH and LH-releasing hormone
4. The neuroendocrine control of the menstrual cycle
5. Receptor-binding affinity of gonadotropin-releasing hormone analogs: Analysis by radioligand-receptor assay
6. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: An overview
7. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis
8. Contrasting effects of a gonadotropin-releasing hormone agonist and antagonist on the secretion of free alpha subunit
9. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: Further evidence for the role of GnRH during the LH surge
10. Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix)
11. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): Evidence from the use of two GnRH antagonists
12. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: Studies in postmenopausal women
13. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetroreliz in healthy female volunteers
14. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle
15. Inhibin A and inhibin B responses to gonadotropin withdrawal depends on stage of follicle development
16. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: Assessment of neuroendocrine and androgen dynamics
17. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix)
18. Ovarian stimulation with HMG: Results of a prospective randomized phase Ill European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetroreliz and the LHRH-agonist buserelin. European Cetrorelix Study Group
19. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
20. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
21. Treatment with gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicte stimulating hormone is effective, safe and convenient: Results of a controlled randomized multicentre trial
22. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrerelix): A pilot study with minimal stimulation
23. Supppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
24. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix)
25. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
26. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles
27. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program
28. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: A pilot study
29. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: Agonists and antagonists
30. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
31. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix
32. Results of a prospective, randomized, multicenter study to assess the efficacy and safety of a gonadotropin releasing hormone (GnRH) antagonist-Org 37462 (ganirelix acetate) treatment in women undergoing controlled ovarian hyperstimulation (COH)
33. Embryo implantation: The Rubicon for GnRH antagonists
34. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles
35. Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone
36. Impact of a GnRH antagonist on the endometrium in women undergoing IVF
37. Diagnosis, prevention and management of ovarian hyperstimulation syndrome
38. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility
39. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist
40. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?
41. 'Medical oophorectomy' using a long-acting GNRH agonist: A possible new approach to the treatment of endometriosis
42. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: Assessment by magnetic resonance imaging
43. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix
44. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix
45. Precocious puberty
46. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone: A preliminary report
47. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin)
48. The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia
49. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
50. LH-RH analogues: I. Their impact on reproductive medicine
51. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis
52. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
53. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord